Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
May 28, 2026
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
May 27, 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
May 26, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
May 25, 2026
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
May 24, 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
May 23, 2026
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
May 21, 2026
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
May 20, 2026
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
May 18, 2026
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 16, 2026
←
Previous Page
1
2
3
Next Page
→